BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 23773867)

  • 1. Waldenström's macroglobulinemia: treatment approaches for newly diagnosed and relapsed disease.
    Hodge LS; Ansell SM
    Transfus Apher Sci; 2013 Aug; 49(1):19-23. PubMed ID: 23773867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines.
    Ansell SM; Kyle RA; Reeder CB; Fonseca R; Mikhael JR; Morice WG; Bergsagel PL; Buadi FK; Colgan JP; Dingli D; Dispenzieri A; Greipp PR; Habermann TM; Hayman SR; Inwards DJ; Johnston PB; Kumar SK; Lacy MQ; Lust JA; Markovic SN; Micallef IN; Nowakowski GS; Porrata LF; Roy V; Russell SJ; Short KE; Stewart AK; Thompson CA; Witzig TE; Zeldenrust SR; Dalton RJ; Rajkumar SV; Gertz MA
    Mayo Clin Proc; 2010 Sep; 85(9):824-33. PubMed ID: 20702770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
    Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
    Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Waldenström's macroglobulinemia as a diagnostic challenge: case report.
    Budimir I; Nikolić M; Pusić MS; Hrabar D; Ljubicić N; Duvnjak M; Supanc V; Nikolac I; Babić N; Sokcević M
    Acta Clin Croat; 2014 Mar; 53(1):94-7. PubMed ID: 24974671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
    Dimopoulos MA; Chen C; Kastritis E; Gavriatopoulou M; Treon SP
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):110-7. PubMed ID: 20371443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
    Kyle RA; Treon SP; Alexanian R; Barlogie B; Björkholm M; Dhodapkar M; Lister TA; Merlini G; Morel P; Stone M; Branagan AR; Leblond V
    Semin Oncol; 2003 Apr; 30(2):116-20. PubMed ID: 12720119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How we treat Waldenström's macroglobulinemia.
    Dimopoulos MA; Merlini G; Leblond V; Anagnostopoulos A; Alexanian R
    Haematologica; 2005 Jan; 90(1):117-25. PubMed ID: 15642678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.
    Dimopoulos MA; Gertz MA; Kastritis E; Garcia-Sanz R; Kimby EK; Leblond V; Fermand JP; Merlini G; Morel P; Morra E; Ocio EM; Owen R; Ghobrial IM; Seymour J; Kyle RA; Treon SP
    J Clin Oncol; 2009 Jan; 27(1):120-6. PubMed ID: 19047284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors and indications for treatment of Waldenström's Macroglobulinemia.
    Kyle RA; Ansell SM; Kapoor P
    Best Pract Res Clin Haematol; 2016 Jun; 29(2):179-186. PubMed ID: 27825464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the treatment of Waldenström's macroglobulinemia.
    Johnson SA
    Expert Rev Anticancer Ther; 2006 Mar; 6(3):329-34. PubMed ID: 16503850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia.
    Vitolo U; Ferreri AJ; Montoto S
    Crit Rev Oncol Hematol; 2008 Aug; 67(2):172-85. PubMed ID: 18499469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel agents in the treatment of Waldenström's macroglobulinemia.
    Treon SP; Hatjiharissi E; Leleu X; Moreau AS; Roccaro A; Hunter ZR; Soumerai JD; Ciccarelli B; Xu L; Sacco A; Ngo HT; Jia X; Yang C; Adamia S; Branagan AR; Ho AW; Santos DD; Tournilhac O; Manning RJ; Leduc R; O'Connor K; Nelson M; Patterson CJ; Ghobrial I
    Clin Lymphoma Myeloma; 2007 Aug; 7 Suppl 5():S199-206. PubMed ID: 17877845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Waldenström's macroglobulinemia.
    Dimopoulos MA; Anagnostopoulos A
    Best Pract Res Clin Haematol; 2005; 18(4):747-65. PubMed ID: 16026748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
    Weber D; Treon SP; Emmanouilides C; Branagan AR; Byrd JC; Bladé J; Kimby E
    Semin Oncol; 2003 Apr; 30(2):127-31. PubMed ID: 12720121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Waldenstrom's macroglobulinemia in the era of immunotherapy.
    Vaxman I; Gertz M
    Leuk Lymphoma; 2020 Jun; 61(6):1292-1304. PubMed ID: 31960730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of plasmapheresis in Waldenström's macroglobulinemia.
    Stone MJ; Bogen SA
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):238-40. PubMed ID: 23522642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of Waldenstrom's macroglobulinemia.
    McDermott MK; Bell EM
    Clin J Oncol Nurs; 1999 Jul; 3(3):107-11. PubMed ID: 10690041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
    Treon SP; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Sheehy P; Manning RJ; Patterson CJ; Tripsas C; Arcaini L; Pinkus GS; Rodig SJ; Sohani AR; Harris NL; Laramie JM; Skifter DA; Lincoln SE; Hunter ZR
    N Engl J Med; 2012 Aug; 367(9):826-33. PubMed ID: 22931316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Waldenstrom's macroglobulinemia.
    Singhal N; Bapsy PP; Babu KG; Sahoo TP
    J Assoc Physicians India; 2004 Dec; 52():981-5. PubMed ID: 15884458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
    Kapoor P; Ansell SM; Fonseca R; Chanan-Khan A; Kyle RA; Kumar SK; Mikhael JR; Witzig TE; Mauermann M; Dispenzieri A; Ailawadhi S; Stewart AK; Lacy MQ; Thompson CA; Buadi FK; Dingli D; Morice WG; Go RS; Jevremovic D; Sher T; King RL; Braggio E; Novak A; Roy V; Ketterling RP; Greipp PT; Grogan M; Micallef IN; Bergsagel PL; Colgan JP; Leung N; Gonsalves WI; Lin Y; Inwards DJ; Hayman SR; Nowakowski GS; Johnston PB; Russell SJ; Markovic SN; Zeldenrust SR; Hwa YL; Lust JA; Porrata LF; Habermann TM; Rajkumar SV; Gertz MA; Reeder CB
    JAMA Oncol; 2017 Sep; 3(9):1257-1265. PubMed ID: 28056114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.